JPS6346043B2 - - Google Patents

Info

Publication number: JPS6346043B2
Authority: JP; Japan
Prior art keywords: emulsion; heparin; anticancer substance; cortisone; present
Prior art date: 1984-11-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP59237759A

Other languages

English (en)

Japanese (ja)

Other versions

JPS61118316A (ja

Inventor

Toshinobu Aoyama

Shingo Nagamitsu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

KAYAKU KK

Original Assignee

KAYAKU KK

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-11-12

Filing date

1984-11-12

Publication date

1988-09-13

1984-11-12 Application filed by KAYAKU KK filed Critical KAYAKU KK

1984-11-12 Priority to JP59237759A priority Critical patent/JPS61118316A/ja

1986-06-05 Publication of JPS61118316A publication Critical patent/JPS61118316A/ja

1988-09-13 Publication of JPS6346043B2 publication Critical patent/JPS6346043B2/ja

Status Granted legal-status Critical Current

Links

239000000126 substance Substances 0.000 claims description 15
230000001093 anti-cancer Effects 0.000 claims description 13
239000000839 emulsion Substances 0.000 claims description 12
229920000669 heparin Polymers 0.000 claims description 10
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 7
229960002897 heparin Drugs 0.000 claims description 7
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 6
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 6
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 6
229960004544 cortisone Drugs 0.000 claims description 6
235000008753 Papaver somniferum Nutrition 0.000 claims description 5
240000001090 Papaver somniferum Species 0.000 claims description 5
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 4
239000004094 surface-active agent Substances 0.000 claims description 4
230000001926 lymphatic effect Effects 0.000 claims description 3
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 6
229950009268 zinostatin Drugs 0.000 description 6
101710204212 Neocarzinostatin Proteins 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 4
210000004324 lymphatic system Anatomy 0.000 description 4
201000011510 cancer Diseases 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
229960001008 heparin sodium Drugs 0.000 description 3
210000002751 lymph Anatomy 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
231100000827 tissue damage Toxicity 0.000 description 3
208000007433 Lymphatic Metastasis Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000009472 formulation Methods 0.000 description 1
208000013210 hematogenous Diseases 0.000 description 1
VLHZUYUOEGBBJB-UHFFFAOYSA-N hydroxy stearic acid Natural products OCCCCCCCCCCCCCCCCCC(O)=O VLHZUYUOEGBBJB-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
-1 polyoxyethylene Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP59237759A 1984-11-12 1984-11-12 リンパ系移行性抗癌物質製剤 Granted JPS61118316A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP59237759A JPS61118316A (ja)	1984-11-12	1984-11-12	リンパ系移行性抗癌物質製剤

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP59237759A JPS61118316A (ja)	1984-11-12	1984-11-12	リンパ系移行性抗癌物質製剤

Publications (2)

Publication Number	Publication Date
JPS61118316A JPS61118316A (ja)	1986-06-05
JPS6346043B2 true JPS6346043B2 (da)	1988-09-13

Family

ID=17020027

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP59237759A Granted JPS61118316A (ja)	1984-11-12	1984-11-12	リンパ系移行性抗癌物質製剤

Country Status (1)

Country	Link
JP (1)	JPS61118316A (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04502113A (ja) *	1988-09-07	1992-04-16	ヴォス―アトラス・アー／エス	特にグリル用の肉焼器

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0314522A (ja) *	1989-06-12	1991-01-23	Shingo Nagamitsu	化学・免疫学的抗癌物質製剤
JP2007075129A (ja) *	2005-09-09	2007-03-29	Okayama Univ	人工肘関節

1984
- 1984-11-12 JP JP59237759A patent/JPS61118316A/ja active Granted

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04502113A (ja) *	1988-09-07	1992-04-16	ヴォス―アトラス・アー／エス	特にグリル用の肉焼器

Also Published As

Publication number	Publication date
JPS61118316A (ja)	1986-06-05

Similar Documents

Publication	Publication Date	Title
US5104656A (en)	1992-04-14	Percutaneous treatment with a high potency non-steroidal anti-inflammatory agent
Hino et al.	2000	Basic study for stabilization of w/o/w emulsion and its application to transcatheter arterial embolization therapy
JP3689791B2 (ja)	2005-08-31	タキソイドに基づく新規な組成物
US5403858A (en)	1995-04-04	New compositions containing taxane derivatives
PT98790B (pt)	1999-01-29	Processo para a preparacao de uma composicao farmaceutica contendo florfenicol
JPH0822815B2 (ja)	1996-03-06	高度にフツ素化された有機化合物の安定乳濁液
EP0007595B1 (en)	1983-04-27	Preparations of clotrimazole and process for preparing same
JPS60199833A (ja)	1985-10-09	医薬品、化粧品等用ｗ／ｏ／ｗ型複合エマルジヨンの製造法
EP0314689A1 (en)	1989-05-10	A controlled-release composition for a biologically active material dissolved or dispersed in an l2-phase.
Matsuru et al.	1979	Increased lymphatic delivery of bleomycin by microsphere in oil emulsion and its effect on lymph node metastasis
JP2963537B2 (ja)	1999-10-18	クラリトロマイシンの注射用組成物
JPS61501566A (ja)	1986-07-31	有効成分の可溶化法およびそれにより得られる薬理組成物
JPS63150221A (ja)	1988-06-22	結晶性薬物含有乳化組成物
KR20130139842A (ko)	2013-12-23	플루르비프로펜을 포함하는 국소성 약학적 조성물
EP0143478B1 (en)	1987-07-22	Stable, aqueous, acidic solution of cis-platinum, suitable for injection
AU2001280306A1 (en)	2002-02-13	Combination compositions
JPS6346043B2 (da)	1988-09-13
Hagerman et al.	1973	In vitro binding of mixed micellar solutions of fatty acids and bile salts by cholestyramine
JP2860748B2 (ja)	1999-02-24	安定な酪酸ヒドロコルチゾン含有クリーム剤
EP0383784A4 (en)	1991-01-16	Gelcores
KR20020038595A (ko)	2002-05-23	피부 침투제를 포함하는 국소용 제제 및 그의 용도
JPS59122423A (ja)	1984-07-14	制癌剤含有脂肪乳剤
US3170836A (en)	1965-02-23	Injectable compositions comprising a copper-containing chelate complex compound dispersed in a stabilized oil-in-water emulsion and method of using the same
JPH0272109A (ja)	1990-03-12	両親媒性クリーム
CN100366253C (zh)	2008-02-06	1,2,4-苯并三嗪氧化物制剂

Legal Events

Date	Code	Title	Description
2003-09-13	LAPS	Cancellation because of no payment of annual fees